Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Lab-on-a-Chip & Microfluidics 2017

Lorna Ewart's Biography

Lorna Ewart, Global Strategy Lead, AstraZeneca

Lorna obtained an honours degree in Pharmacology from the University of Aberdeen and a PhD from Sir John Vane’s William Harvey Research Institute, University of London. She joined the Respiratory and Inflammation research area within AstraZeneca as a lead biologist bringing forward projects to candidate drug nomination before moving into pre-clinical drug safety to lead a safety pharmacology team delivering across multiple therapeutic areas. Lorna spent two years in Gothenburg, Sweden as the therapy area lead toxicologist for Respiratory and Inflammation therapy area before returning to Cambridge, UK where she heads the Centre of Excellence for Microphyisological Systems within AstraZeneca’s Innovative Medicines Unit. Here she has established strategic collaborations with leading external academics as well as ensured technology transfer into AstraZeneca. Scientifically, Lorna is passionate about the translation of preclinical science to patient outcome. She has over 25 peer reviewed publications and is a fellow of the Royal Society of Biology and the British Pharmacological Society.

Lorna Ewart Image

Navigating Tissue Chips from Development to Dissemination: A Pharmaceutical Industry Perspective

Thursday, 11 May 2017 at 14:30

Add to Calendar ▼

Microphysiological systems (best recognized as ‘organ chips’) are a rapidly developing in vitro technology that is providing unique opportunities to model the complexity of in vivo biology. The growing debate about the role of animal studies in a challenging rate of drug development attrition for both efficacy and safety has prompted excitement for the potential for greater clinical relevance of human-sourced microphysiological systems over traditional animal models. Attaining the full promise and impact of this innovation will take a very deliberate process of evolution. This presentation will outline a framework used at AstraZeneca to select the context of use for microphysiological systems and exemplify the type of data that is possible to achieve from such systems in drug development. Lastly, it will share an ongoing partnership between pharmaceutical industry scientists and NCATS that is facilitating the evolution of this technology.

Add to Calendar ▼2017-05-10 00:00:002017-05-11 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics 2017Lab-on-a-Chip and Microfluidics 2017 in Holiday Inn City Centre, Munich, GermanyHoliday Inn City Centre, Munich,